Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer

BET bromodomain inhibitors (BBDI) are candidate therapeutic agents in triple-negative breast cancer (TNBC) and other cancer types, but inherent and acquired resistance to BBDIs limit their potential clinical use. Using CRISPR and small molecule inhibitor screens combined with comprehensive molecular...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Cell
Main Authors: Shu, Shaokun, Wu, Hua-Jun, Ge, Jennifer Y., Zeid, Rhamy, Harris, Isaac S., Jovanović, Bojana, Murphy, Katherine, Wang, Binbin, Qiu, Xintao, Endress, Jennifer E., Reyes, Jaime, Lim, Klothilda, Font-Tello, Alba, Syamala, Sudeepa, Xiao, Tengfei, Reddy Chilamakuri, Chandra Sekhar, Papachristou, Evangelia K., D’Santos, Clive, Anand, Jayati, Hinohara, Kunihiko, Li, Wei, McDonald, Thomas O., Luoma, Adrienne, Modiste, Rebecca J., Nguyen, Quang-De, Michel, Brittany, Cejas, Paloma, Kadoch, Cigall, Jaffe, Jacob D., Wucherpfennig, Kai W., Qi, Jun, Liu, X. Shirley, Long, Henry, Brown, Myles, Carroll, Jason S., Brugge, Joan S., Bradner, James, Michor, Franziska, Polyak, Kornelia
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306005/
https://ncbi.nlm.nih.gov/pubmed/32416067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molcel.2020.04.027
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker